Dataset Information

ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.

ABSTRACT: Somatic mutations in cancers affecting protein coding genes can give rise to potentially therapeutic neoepitopes. These neoepitopes can guide Adoptive Cell Therapies and Peptide- and RNA-based Neoepitope Vaccines to selectively target tumor cells using autologous patient cytotoxic T-cells. Currently, researchers have to independently align their data, call somatic mutations and haplotype the patient's HLA to use existing neoepitope prediction tools. We present ProTECT, a fully automated, reproducible, scalable, and efficient end-to-end analysis pipeline to identify and rank therapeutically relevant tumor neoepitopes in terms of potential immunogenicity starting directly from raw patient sequencing data, or from pre-processed data. The ProTECT pipeline encompasses alignment, HLA haplotyping, mutation calling (single nucleotide variants, short insertions and deletions, and gene fusions), peptide:MHC binding prediction, and ranking of final candidates. We demonstrate the scalability, efficiency, and utility of ProTECT on 326 samples from the TCGA Prostate Adenocarcinoma cohort, identifying recurrent potential neoepitopes from TMPRSS2-ERG fusions, and from SNVs in SPOP. We also compare ProTECT with results from published tools. ProTECT can be run on a standalone computer, a local cluster, or on a compute cloud using a Mesos backend. ProTECT is highly scalable and can process TCGA data in under 30 min per sample (on average) when run in large batches. ProTECT is freely available at https://www.github.com/BD2KGenomics/protect.

SUBMITTER: Rao AA

PROVIDER: S-EPMC7683782 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.

Rao Arjun A AA Madejska Ada A AA Pfeil Jacob J Paten Benedict B Salama Sofie R SR Haussler David D

Frontiers in immunology 20201110

Somatic mutations in cancers affecting protein coding genes can give rise to potentially therapeutic neoepitopes. These neoepitopes can guide Adoptive Cell Therapies and Peptide- and RNA-based Neoepitope Vaccines to selectively target tumor cells using autologous patient cytotoxic T-cells. Currently, researchers have to independently align their data, call somatic mutations and haplotype the patient's HLA to use existing neoepitope prediction tools. We present ProTECT, a fully automated, reprodu ...[more]

PMID: 33244314

Similar Datasets

Project description:BACKGROUND: Development of computational tools that can accurately predict presence and location of B-cell epitopes on pathogenic proteins has a valuable application to the field of vaccinology. Because of the highly variable yet enigmatic nature of B-cell epitopes, their prediction presents a great challenge to computational immunologists. METHODS: We propose a method, BEEPro (B-cell epitope prediction by evolutionary information and propensity scales), which adapts a linear averaging scheme on 16 properties using a support vector machine model to predict both linear and conformational B-cell epitopes. These 16 properties include position specific scoring matrix (PSSM), an amino acid ratio scale, and a set of 14 physicochemical scales obtained via a feature selection process. Finally, a three-way data split procedure is used during the validation process to prevent over-estimation of prediction performance and avoid bias in our experiment results. RESULTS: In our experiment, first we use a non-redundant linear B-cell epitope dataset curated by Sollner et al. for feature selection and parameter optimization. Evaluated by a three-way data split procedure, BEEPro achieves significant improvement with the area under the receiver operating curve (AUC) = 0.9987, accuracy = 99.29%, mathew's correlation coefficient (MCC) = 0.9281, sensitivity = 0.9604, specificity = 0.9946, positive predictive value (PPV) = 0.9042 for the Sollner dataset. In addition, the same parameters are used to evaluate performance on other independent linear B-cell epitope test datasets, BEEPro attains an AUC which ranges from 0.9874 to 0.9950 and an accuracy which ranges from 93.73% to 97.31%. Moreover, five-fold cross-validation on one benchmark conformational B-cell epitope dataset yields an accuracy of 92.14% and AUC of 0.9066. CONCLUSIONS: Compared with other current models, our method achieves a significant improvement with respect to AUC, accuracy, MCC, sensitivity, specificity, and PPV. Thus, we have shown that an appropriate combination of evolutionary information and propensity scales with a support vector machine model can significantly enhance the prediction performance of both linear and conformational B-cell epitopes.

Project description:High genetic heterogeneity in the hepatitis C virus (HCV) is the major challenge of the development of an effective vaccine. Existing studies for developing HCV vaccines have mainly focused on T-cell immune response. However, identification of linear B-cell epitopes that can stimulate B-cell response is one of the major tasks of peptide-based vaccine development. Owing to the variability in B-cell epitope length, the prediction of B-cell epitopes is much more complex than that of T-cell epitopes. Furthermore, the motifs of linear B-cell epitopes in different pathogens are quite different (e. g. HCV and hepatitis B virus). To cope with this challenge, this work aims to propose an HCV-customized sequence-based prediction method to identify B-cell epitopes of HCV.This work establishes an experimentally verified dataset comprising the B-cell response of HCV dataset consisting of 774 linear B-cell epitopes and 774 non B-cell epitopes from the Immune Epitope Database. An interpretable rule mining system of B-cell epitopes (IRMS-BE) is proposed to select informative physicochemical properties (PCPs) and then extracts several if-then rule-based knowledge for identifying B-cell epitopes. A web server Bcell-HCV was implemented using an SVM with the 34 informative PCPs, which achieved a training accuracy of 79.7% and test accuracy of 70.7% better than the SVM-based methods for identifying B-cell epitopes of HCV and the two general-purpose methods. This work performs advanced analysis of the 34 informative properties, and the results indicate that the most effective property is the alpha-helix structure of epitopes, which influences the connection between host cells and the E2 proteins of HCV. Furthermore, 12 interpretable rules are acquired from top-five PCPs and achieve a sensitivity of 75.6% and specificity of 71.3%. Finally, a conserved promising vaccine candidate, PDREMVLYQE, is identified for inclusion in a vaccine against HCV.This work proposes an interpretable rule mining system IRMS-BE for extracting interpretable rules using informative physicochemical properties and a web server Bcell-HCV for predicting linear B-cell epitopes of HCV. IRMS-BE may also apply to predict B-cell epitopes for other viruses, which benefits the improvement of vaccines development of these viruses without significant modification. Bcell-HCV is useful for identifying B-cell epitopes of HCV antigen to help vaccine development, which is available at http://e045.life.nctu.edu.tw/BcellHCV.

Project description:BACKGROUND:The application of peptide based diagnostics and therapeutics mimicking part of protein antigen is experiencing renewed interest. So far selection and design rationale for such peptides is usually driven by T-cell epitope prediction, available experimental and modelled 3D structure, B-cell epitope predictions such as hydrophilicity plots or experience. If no structure is available the rational selection of peptides for the production of functionally altering or neutralizing antibodies is practically impossible. Specifically if many alternative antigens are available the reduction of required synthesized peptides until one successful candidate is found is of central technical interest. We have investigated the integration of B-cell epitope prediction with the variability of antigen and the conservation of patterns for post-translational modification (PTM) prediction to improve over state of the art in the field. In particular the application of machine-learning methods shows promising results. RESULTS:We find that protein regions leading to the production of functionally altering antibodies are often characterized by a distinct increase in the cumulative sum of three presented parameters. Furthermore the concept to maximize antigenicity, minimize variability and minimize the likelihood of post-translational modification for the identification of relevant sites leads to biologically interesting observations. Primarily, for about 50% of antigen the approach works well with individual area under the ROC curve (AROC) values of at least 0.65. On the other hand a significant portion reveals equivalently low AROC values of < or = 0.35 indicating an overall non-Gaussian distribution. While about a third of 57 antigens are seemingly intangible by our approach our results suggest the existence of at least two distinct classes of bioinformatically detectable epitopes which should be predicted separately. As a side effect of our study we present a hand curated dataset for the validation of protectivity classification. Based on this dataset machine-learning methods further improve predictive power to a class separation in an equilibrated dataset of up to 83%. CONCLUSION:We present a computational method to automatically select and rank peptides for the stimulation of potentially protective or otherwise functionally altering antibodies. It can be shown that integration of variability, post-translational modification pattern conservation and B-cell antigenicity improve rational selection over random guessing. Probably more important, we find that for about 50% of antigen the approach works substantially better than for the overall dataset of 57 proteins. Essentially as a side effect our method optimizes for presumably best applicable peptides as they tend to be likely unmodified and as invariable as possible which is answering needs in diagnosis and treatment of pathogen infection. In addition we show the potential for further improvement by the application of machine-learning methods, in particular Random Forests.

Dataset Information

ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.

Publications

ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets